Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh 140401, Punjab, India.
Department of Pharmacology, GHG Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana 141104, Punjab, India.
Int J Mol Sci. 2021 Jan 30;22(3):1413. doi: 10.3390/ijms22031413.
Neurodegeneration is the pathological condition, in which the nervous system or neuron loses its structure, function, or both, leading to progressive degeneration or the death of neurons, and well-defined associations of tissue system, resulting in clinical manifestations. Neuroinflammation has been shown to precede neurodegeneration in several neurodegenerative diseases (NDs). No drug is yet known to delay or treat neurodegeneration. Although the etiology and potential causes of NDs remain widely indefinable, matrix metalloproteinases (MMPs) evidently have a crucial role in the progression of NDs. MMPs, a protein family of zinc (Zn)-containing endopeptidases, are pivotal agents that are involved in various biological and pathological processes in the central nervous system (CNS). The current review delineates the several emerging evidence demonstrating the effects of MMPs in the progression of NDs, wherein they regulate several processes, such as (neuro)inflammation, microglial activation, amyloid peptide degradation, blood brain barrier (BBB) disruption, dopaminergic apoptosis, and α-synuclein modulation, leading to neurotoxicity and neuron death. Published papers to date were searched via PubMed, MEDLINE, etc., while using selective keywords highlighted in our manuscript. We also aim to shed a light on pathophysiological effect of MMPs in the CNS and focus our attention on its detrimental and beneficial effects in NDs, with a special focus on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple sclerosis (MS), and Huntington's disease (HD), and discussed various therapeutic strategies targeting MMPs, which could serve as potential modulators in NDs. Over time, several agents have been developed in order to overcome challenges and open up the possibilities for making selective modulators of MMPs to decipher the multifaceted functions of MMPs in NDs. There is still a greater need to explore them in clinics.
神经退行性变是一种病理状态,在此状态下,神经系统或神经元丧失其结构、功能或两者兼失,导致神经元进行性退化或死亡,以及组织系统的明确关联,从而导致临床症状。神经炎症已被证明在几种神经退行性疾病(NDs)中先于神经退行性变发生。目前还没有药物可以延缓或治疗神经退行性变。尽管 NDs 的病因和潜在原因仍广泛未定义,但基质金属蛋白酶(MMPs)显然在 NDs 的进展中起着至关重要的作用。MMPs 是一类含锌(Zn)的内肽酶的蛋白质家族,是参与中枢神经系统(CNS)中各种生物和病理过程的关键因子。本综述阐述了几项新出现的证据,这些证据表明 MMPs 在 NDs 进展中的作用,它们调节多种过程,如(神经)炎症、小胶质细胞激活、淀粉样肽降解、血脑屏障(BBB)破坏、多巴胺能细胞凋亡和α-突触核蛋白调节,导致神经毒性和神经元死亡。迄今为止,通过 PubMed、MEDLINE 等检索发表的论文,并使用我们手稿中突出的选择性关键字。我们还旨在阐明 MMPs 在 CNS 中的病理生理作用,并关注其在 NDs 中的有害和有益作用,特别关注帕金森病(PD)、肌萎缩侧索硬化症(ALS)、阿尔茨海默病(AD)、多发性硬化症(MS)和亨廷顿病(HD),并讨论了针对 MMPs 的各种治疗策略,这些策略可能成为 NDs 的潜在调节剂。随着时间的推移,已经开发出几种药物,以克服挑战并为开发 MMP 的选择性调节剂开辟可能性,以阐明 MMPs 在 NDs 中的多方面功能。仍需要在临床上进一步探索它们。